Though the overall incidence of head and neck cancers has fallen in the United States, the rate of oropharyngeal cancers(chiefly, tonsil and base of tongue) is stagnant and appears to be rising is certain populations and these trends are likely due to oncogenic human papillomavirus (HPV) infection.
Get the full story...
For women with human papillomavirus (HPV) infection, use of the HPV-16/18 vaccine will not accelerate reduction of the virus and should not be used to treat the infection, according to a study in the August 15 issue of JAMA.
Get the full story...
A second cervical cancer vaccine has passed a key clinical trial and its maker is seeking to use the vaccine in countries around the world. As VOA's Carol Pearson reports, more women may be able to use this new vaccine by drug giant GlaxoSmithKline than use the first cervical cancer vaccine, Gardisil.
Get the full story...
A vaccine against the sexually transmitted virus that can cause cervical cancer went on sale Wednesday in Italy, the first European Union nation to offer the vaccine free for 12-year-old girls, the Italian Health Ministry said.
Get the full story...
The most common sexually transmitted virus in the US is genital human papillomavirus (HPV) infection, with 20 million Americans currently infected and another 6.2 million becoming infected each year. Although HPV causes serious damage to women's health, including cervical cancer, awareness of the disease is surprisingly low.
Read the full story
A test for the two strains of human papillomavirus responsible for most cervical cancers is under study.
Read the full story
Temple University Hospital's Center For Women's Health is participating in a national study to determine the safety and effectiveness of an investigational treatment for cervical dysplasia. According to the American Cancer Society, approximately 500,000 women are diagnosed with high-grade cervical dysplasia each year, with roughly 10,000 cases progressing to cervical cancer.
Read the full story
